Plagued by production issues, Pfizer aims to shift EpiPen work to Mylan-Upjohn merger
Mylans EpiPen has had a troubled few years—to say the least—with federal prosecutors knocking at the door and shortages plaguing production. Now, with Mylan and Pfizers generic business Upjohn working on a merger, a new EpiPen manufacturer could be in the cards.
Mylan and Pfizer are in talks to move EpiPens production to the new merged generics company, which is expected to take flight in mid-2020. A spokeswoman for Pfizer, which manufactures the drug under its Meridian Medical Technologies unit, said talks are ongoing and terms have yet to be finalized.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!